Because of its efficacy against T315I-mutated BCR-ABL, a mutation that confers resistance to all other BCR-ABL TKIs (Cortes et al., 2012), this third generation drug is used to treat CML resistant to first line treatments. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.